Hanmi, Spectrum enter agreement over neutropenia treatment

Published: 2012-02-02 06:58:00

Updated: 2012-02-02 06:58:00

Hanmi Pharmaceutical said Tuesday that it has signed a co-development and commercialization Agreement with the US based Spectrum Pharmaceuticals on Hanmi’s new biopharmaceutical LAPS-GCSF (HM10460A/neutropenia drug).

LAPS-GCSF is a Biobetter product that utilizes Hanmi's proprietary platform ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK